Abrocitinib as a novel treatment for lichen sclerosus

Abstract

A total of 10 patients were recruited to evaluate the efficacy and safety of abrocitinib for lichen sclerosus. All patients reported rapid control of pruritus at week 2 and achieved Investigator's Global Assessment 0 or 1 at week 12. This study suggests that the abrocitinib could be an effective and safe treatment option for LS, based on the significant improvements in investigator evaluation, patientreported outcomes, and skin imaging findings.

Abrocitinib as a Novel Treatment for Multiple Skin Disorders: 3 Case Reports and a Scoping Review

“…Abrocitinib was utilized off-label for the treatment of 16 skin disorders (28 cases). These mainly include lichen sclerosus (10 cases), 4 AA (5 cases), 3,[5][6][7] and lichenoid amyloidosis (2 cases). 1 Additionally, other treated conditions encompassed eruptive pruritic papular porokeratosis, 8 Hailey-Hailey disease, 9 necrobiosis lipoidica, 10 occupational airborne allergic contact dermatitis, 2 Netherton syndrome, 11 oral lichen planus, 12 nipple and areola eczema, 13 prurigo nodularis, 14 PG, LV, and HS, each presenting 1 case.…”

“…Abrocitinib, inhibitor of JAK1, has recently shown promising results in the off-label treatment of some skin diseases associated with JAK activity, including alopecia areata (AA), and others. 4 , 5 Herein, we present a case series comprising three patients, each diagnosed with pyoderma gangrenosum (PG), livedoid vasculopathy (LV), or hidradenitis suppurativa (HS). These patients exhibited a favorable response to abrocitinib following inadequate outcomes with conventional therapies.…”

A Case of Perioral Dermatitis Successfully Treated with Abrocitinib

“… 3 It effectively inhibits numerous critical cytokine signaling pathways, including those mediated by interferon (IFN)-γ, interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-17. In addition to its use in AD, abrocitinib has demonstrated effectiveness in treating various other skin disorders, such as alopecia areata, 4 plaque psoriasis, 5 lichen sclerosus, 6 Hailey-Hailey disease, 7 necrobiosis lipoidica, 8 prurigo nodularis, 9 primary cutaneous lichenoid amyloidosis, 10 and several others.…”

Treatment of plasma cell balanitis associated with male genital lichen sclerosus using abrocitinib

“… 1 Male genital lichen sclerosus (MGLS) is characterized by atrophic ivory plaques, and some scholars link it to autoimmunity. 2 Both PCB and MGLS can arise from redundant prepuce and exposure to chronic irritation such as prolonged urine infiltration, making their simultaneous occurrence in a patient possible. 3 Treatments for PCB include calcineurin inhibitors, steroid ointments, and circumcision.…”

“… 4 Previous study has shed light on abrocitinib’s promising role in the treatment of MGLS, offering hope to those afflicted by this challenging dermatologic disorder. 2 …”